drugset / Trial / NCT00870948
Phase 1 BA Study, Single Center With Healthy Volunteers
RandomizedParallel-groupOpen-labelBasic science
Summary
Single dose in healthy volunteers to assess bioavailability (amount of study drug in the system) between different formulations of ABT-874.
Timeline
- Start
- 2009-01
- Primary completion
- 2009-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | briakinumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | briakinumab | Monoclonal antibody | 700 mg | Subcutaneous |
Indications
No indication recorded.